Pfizer, BioNTech announce EUA for bivalent COVID vaccine for children under 5

Pfizer (PFE) and BioNTech SE (BNTX) announced the U.S. Food and Drug Administration granted Emergency Use Authorization, or EUA, of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-microgram dose in the three-dose primary series for children 6 months through 4 years of age. Children in this age group can receive a primary series consisting of two 3-microgram doses of the original Pfizer-BioNTech COVID-19 Vaccine followed by a third 3-microgram dose of the bivalent vaccine to complete the primary series. Vaccine doses can be delivered immediately upon receipt of a recommendation from the U.S. Centers for Disease Control and Prevention, the companies stated.